A Phase IV Study of Elunate® (Fruquintinib) in Chinese Patients

CompletedOBSERVATIONAL
Enrollment

3,005

Participants

Timeline

Start Date

April 20, 2019

Primary Completion Date

September 27, 2022

Study Completion Date

September 27, 2022

Conditions
Patient Safety
Interventions
DRUG

Elunate®

The recommended dose is 5 mg once daily (1 capsule, each capsule contains 5 mg of fruquintinib); three weeks of continuous drug administration followed by one week of drug free period (4 weeks as one treatment cycle).

Trial Locations (1)

Unknown

Shanghai Dongfang Hospital, Shanghai

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Hutchmed

INDUSTRY